Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT00760929
First received: September 25, 2008
Last updated: November 1, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2010
  Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: July 26, 2016
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):